| Literature DB >> 29182540 |
Alena Soboleva1,2, Maria Vikhnina3,4, Tatiana Grishina5, Andrej Frolov6,7.
Abstract
Glycation is a non-enzymatic post-translational modification of proteins, formed by the reaction of reducing sugars and α-dicarbonyl products of their degradation with amino and guanidino groups of proteins. Resulted early glycation products are readily involved in further transformation, yielding a heterogeneous group of advanced glycation end products (AGEs). Their formation is associated with ageing, metabolic diseases, and thermal processing of foods. Therefore, individual glycation adducts are often considered as the markers of related pathologies and food quality. In this context, their quantification in biological and food matrices is required for diagnostics and establishment of food preparation technologies. For this, exhaustive protein hydrolysis with subsequent amino acid analysis is the strategy of choice. Thereby, multi-step enzymatic digestion procedures ensure good recoveries for the most of AGEs, whereas tandem mass spectrometry (MS/MS) in the multiple reaction monitoring (MRM) mode with stable isotope dilution or standard addition represents "a gold standard" for their quantification. Although the spectrum of quantitatively assessed AGE structures is continuously increases, application of untargeted profiling techniques for identification of new products is desired, especially for in vivo characterization of anti-glycative systems. Thereby, due to a high glycative potential of plant metabolites, more attention needs to be paid on plant-derived AGEs.Entities:
Keywords: LC-MS/MS; advanced glycation end products (AGEs); amino acid analysis; exhaustive hydrolysis; glycation; glycation adducts; glyoxalase; stable isotope dilution; standard addition
Mesh:
Substances:
Year: 2017 PMID: 29182540 PMCID: PMC5751160 DOI: 10.3390/ijms18122557
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1The major pathways of AGE formation: oxidative glycosylation [12], Namiki pathway [13], enolization [14], oxidative [15] and non-oxidative [16] degradation of early glycation products, polyol [17], and lipid peroxidation [18]. 3-DG, 3-deoxyglucasone; GO, glyoxal; MGO, methylglyoxal.
Figure 2Advanced glycation end products (AGEs) originating from lysine (N-(carboxymethyl)lysine, CML; N-(formyl)lysine; pyrraline), arginine (N-(carboxyethyl)arginine, CEA; N-(5-methyl-4-oxo-5-hydroimidazo-linone-2-yl)ornithine, MG-H1; argpyrimidine) and of cross-link nature (pentosidine; vesperlysine A; glyoxal-derived lysine dimer, GOLD).
Overview of analytical techniques employed in analysis of free and protein-bound glycation adducts.
| # | Object | Analyzed Adducts | Methodology | Ref | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Technique | Protein Isolation | Protein Hydrolysis | Derivatization (Reagents) | Separation | Detection | Standardization | ||||
| 1 | FFL | CML | GC-MS | - | - | Acetylation (Ac2O) | 7%-cyanopropyl/7%-phenylmethyl coated capillary column | EI-SF, SIM | external | [ |
| 2 | lense proteins | CML | GC-MS | cold water extraction, dialysis | acid | Acetylation (Ac2O) | SPB-1 capillary column (poly(dimethyl siloxane)), SE-30 capillary column (dimethylpolysiloxane) carrier helium | FID | external | [ |
| 3 | collagen | CML, CML-OH, FL | GC-MS | CCl4/MeOH extraction | acid | esterification (HCL, MeOH, CH2Cl2, C4F6O3) | DB-5 capillary column ((5%-phenyl)-methylpolysiloxane) | EI-Q-MS, SIM | external | [ |
| 4 | hemo-globin | CM-Ala, CM-Val, CM-Leu, CM-Ile, CM-Phe, CM-Gly, α-CML, ε-CML, bis-CML | GC-MS | - | acid | acetylation/esterification (Ac2O, | DB-5 capillary column ((5%-phenyl)- methylpolysiloxane), DB-1701capillary column (14%-cyanopropyl- phenyl)- methylpolysiloxane) carrier helium | PICI, EI-QqQ, CAD | - | [ |
| 5 | BSA | AGEs, poly- | Py-GC-MS | - | pyrolysis | - | DBl capillary column (100% dimethylpolysiloxane) | EI-IT-MS | - | [ |
| 6 | HSA | CML, CEL, MG-H, Glarg, 3-DG-H, THP, FL, pentosidine, CEL, AP, GOLD, MOLD, pyrraline | off-line HPLC-MALDI-TOF | - | enzymatic 1, acid | AQC | RP, analytical column NOVAPAK4 ODS (C18), NOVAPAK4 ODS (C18) Sentry guard column A: NaAc 140 mmol/L, TEA 17 mmol/L, pH 5.05, B: ACN, C: water | MALDI-TOF | internal, external | [ |
| 7 | BSA | HPLC-MS | - | enzymatic 1 | - | RP, Nucleosil 100-5 NH2 column (aminopropyl modified silica), A: water, B: MeOH | ESI-IT-MS | internal | [ | |
| 8 | BSA | GODIC, MODIC | HPLC-MS | - | enzymatic 1 | - | RP, YMC- Pack Pro C 18 column, A: 10 mmol/L phosph. buffer (pH 4.0) B: MeOH, gradient | ESI-Q-MS MCA | external | [ |
| 9 | β-lacto-globulin | Maillard reaction products | HPLC-MS | desalting and dialysis | enzymatic 2 | - | RP, Nucleosil 300-5 C18 column, A: 0.115% aq. TFA B: 80% ACN/0.1% aq. TFA | Ex/Em: 210/330 ESI-QqQ | - | [ |
| 10 | BSA, HSA | Pyrraline | HPLC-UV | - | alkaline | - | RP-HPLC, Vydac C18 analytical column, A: 0.1% aq. TFA, B: 50% ACN; A: 0.16% aq. HFBA, B: 0.16% aq. HFBA/50% ACN | UV, 298 nm | external | [ |
| 11 | food samples | CML | HPLC-Fluo | - | acid | OPA | RP, Spherisorb 5 C18 column, A: NaAc buffer (pH 6.7, 0.05 mol/L)/4% MeOH B: MeOH | Fluo Ex/Em: 340/455 | external | [ |
| 12 | FFL | CML | HPLC-Fluo | - | - | OPA | CXC; A: 0.2 mol/L sodium citrate, pH 3.2 B: 0.2 mol/L sodium citrate, 1 mol/L NaCl pH 7.0 | Fluo | - | [ |
| 13 | lense proteins | AGEs | HPLC-Fluo | dialysis | acid, enzymatic 3 | OPA | RP, column packed with RP-18 material A: 0.12% aq. HFBA B: 0.12% aq. HFBA/30% MeOH | Fluo Ex/Em: 340/455 | external | [ |
| 14 | lense proteins | GALA, GOLA, GOLD, CML, CMPM | HPLC-MS | dialysis | acid, enzymatic 4 | OPA | RP, VYDAC column Knauer Eurospher 100 column RP18 A: 0.12% aq. HFBA B: 0.12% aq. HFBA/30% MeOH | ESI-Q-MS | external | [ |
| 15 | lense proteins | AGEs | HPLC-MS/MS | dialysis | acid, enzymatic 5 | - | RP-C18 A: 0.12% aq. HFBA B: 0.12% aq. HFBA/30% MeOH | ESI-QqQ-MS/MS, CAD, MRM | external | [ |
| 16 | beer proteins | FL, ML, pyrraline, formyline, maltosine, MG-H1, AP | HPLC-MS/MS | dialysis | acid, enzymatic 1 | - | RP, Zorbax 100 SB-C18 A: 10 mmol/L aq. NFPA B: 10 mmol/L aq. NFPA/ACN | ESI-QqQ-MS/MS, CAD MRM | external | [ |
| 17 | serum | CML | LC-MS/MS | - | acid | - | HILIC (ZIC) A: 0.1% FA/ACN B: 0.1% aq. FA | ESI-QqQ-MS/MS, MRM | internal | [ |
| 18 | food samples | α-fructosyl-amino acids | HPLC-MS | filtration | - | - | IP-RP, Kinetex core-shell C18 column A: 5 mmol/L aq, NFPA B: 5 mmol/L aq. NFPA/ACN | HESI-Orbitrap | external, internal | [ |
| 19 | cellular and extra-cellular proteins | CML, CEL, pentosidine, GOLD, MOLD, DOLD, FL, AP, pyrraline, MG-H, 3-DG-H | HPLC-MS/MS | - | enzymatic 1 | - | RP, Hypercarb™ columns (carbon) A: 26 mmol/L aq. AM (pH 3.8) B: 26 mmol/L aq. AM (pH 3.8)/ACN | ESI-QqQ-MS/MS CAD MRM | internal | [ |
1 Pepsin, pronase E, aminopeptidase, prolidase; 2 trypsin; 3 pronase E, aminopeptidase; 4 carboxypeptidase Y; 5 proteinase K, carboxypeptidase Y, peptidase, Pronase E, aminopeptidase; %, %(v/v); 3-DG-H, 3-deoxyglucosonederived hydroimidazolone; ACN, acetonitrile; AGEs, advanced glycation end products; AM, ammonium formate; AP, argpyrimidine; aq., aqueous; AQC, 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate; BSA, bovine serum albumin; CAD, collision-activated dissociation; CEL, N-(carboxyethyl)lysine; CXC, cation exchange chromatography; CM-Ala, N-(carboxymethyl)alanine; CM-Gly, N-(carboxymethyl)glycine; CM-Ile, N-(carboxymethyl)isoleucine; CML, N′-(carboxymethyl)lysine; CM-Leu, N-(carboxymethyl)leucine; CML-OH, N-(carboxymethyl)hydroxylysine; CM-Phe, N-(carboxymethyl)phenylalanine; CMPM, [(3-hydroxy-5-hydroxymethyl-2-methyl-pyridin-4-ylmethyl)amino]acetic acid; CM-Val, N-(carboxymethyl)valine; DOLD, 3-deoxyglucosone-derived lysine dimer; EI, electron (impact) ionization; ESI, electrospray ionization; Ex/Em, excitation/emission wavelengths; FA, formic acid; FID, flame ionization; FFL, Nu-formyl-N′-fructose-lysine; FL, fructose-lysine; GALA, N6-(glycoloyl)lysine; GC-MS, gas chromatography–mass spectrometry; Glarg, glyoxal-derived hydroimidazolone; GODIC, 2-ammonio-6-([2-[(4-ammonio-5-oxido-5-oxopentyl)amino]-4,5-dihydro-1H-imidazol-5-ylidene]amino)-hexanoate; GOLA, N-[2-[(5-amino-5-carboxypentyl)amino]-2-oxoethyl]lysine; GOLD, glyoxal-derived lysine dimer; HESI, heated electrospray ionization; HFBA, heptafluorobutyric acid; HILIC, hydrophilic interaction liquid chromatography; HPLC, high-performance liquid chromatography; HSA, human serum albumin; i-But-OH, isobutanal; IP, ion-pairing; IT, ion trap; LC, liquid chromatography; MALDI, matrix assisted laser desorption/ionization MCA—multichannel acquisition; MeOH, methanol; MG-H, methylglyoxal-derived hydroimidazolone; ML, maltulosyllysine; MODIC, 2-ammonio-6-([2-[(4-ammonio-5-oxido-5-oxopentyl) amino]-4-methyl-4,5-dihydro-1H-imidazol-5-ylidene]amino)hexanoate; MOLD, methylglyoxal-derived lysine dimer; MRM, multiple reaction monitoring; MS, mass spectrometry; MS/MS, tandem mass-spectrometry; NFPA, nonafluoropentanoic acid; ODS, octadecyl silica; OPA, o-phthaldialdehyde; PICI, positive ion chemical ionization; PITC, phenylisothiocyanate; Py-GC-MS, pyrolysis GC-MS; QMS, quadrupole mass analyzer; QqQ, triple quadrupole; RP, reversed phase; SF, sector field; SIM, selective ion monitoring; TEA, trimethylamine; TFA, trifluoroacetic acid; THP, N-(4-carboxy-4,6-dimethyl-5,6-dihydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)-ornithine; UV, ultra-violet detection; v/v, ratio by volume; #, number.
Figure 3The overview of protein hydrolysis workflows (alkaline [99], acid [19,115] and enzymatic [19,115,116]), compatible with subsequent chromatography-based analysis. Concentrations: Ba(OH)2, 1.7 mol/L [99]; HCl, 6 N [19,115]; pronase E, two additions of 0.3 unit [19], 400 PU [115], 20 μg [116]; leucine aminopeptidase, 1unit [19], 0.4 unit [115]; carboxypeptidase Y, 0.95 unit [19]; pepsin, 1 FIP-U [115]; prolidase, 1 unit [115]; collagenase, 0.04 mg/mL [116].
Figure 4Stable isotope dilution (A) and standard addition (B) approaches for quantification of glycation adducts.
Application of glycation adduct analysis in medical diagnostics.
| # | Disease | Object | Analyzed Adducts | Main Results | Methodology | Ref. | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Technique | Protein Isolation | Protein Hydrolysis | Derivatization | Separation | Detection | Standardization | ||||||
| 1 | T1DM | serum | CML, pentosidine | increase of AGE levels | HPLC-MS/MS | serum treatment | acid | - | Kinetex HILIC/PFP (CML/pentosidine) A: 5 mmol/L aq. AM B: 100% ACN | ESI-QqQ-MS/MS CAD MRM | internal | [ |
| 2 | DM | rabbit blastocyst cavity fluid | CML | increase of CML levels | HPLC-MS/MS | analysis of free adducts | - | - | RP, C18 A: 0.12% aq. HFBA B: 0.12% aq. HFBA/30% MeOH | ESI-QqQ-MS/MS CAD MRM | internal | [ |
| 3 | DM | rat plasma protein | CML, CEL, Glarg, MG-H1 | increase of AGE levels | HPLC-MS/MS | Ultrafiltra-tion (12 kDa cut-off) | enzymatic 1 | - | RP, carbon Hypercarb™ A: 26 mmol/L AM, pH 3.8, B: ACN | ESI-QqQ-MS/MS CAD MRM | internal | [ |
| 4 | diabetic nephro-pathy | blood from normoalbuminuric subjects (NHDNS) | CML, CEL, MG-HI | increase of AGE levels | HPLC-MS/MS | filtration (10 KDa cutoff) | - | - | RP, C18 Synergy 80 A A: 0.29% aq. HFBA, B: 0.29% aq. HFBA/MeOH | ESI-QqQ-MS/MS CAD MRM | internal | [ |
| 5 | fibrosis | human aged lens capsules | CML, NFL, CMA, NAL, CEA, MG-H1, Pyrraline Glucosepane,MODIC | AGEs in the lens capsule promote fibrosis of lens epithelial cells | HPLC-MS/MS | enzymatic 2 | - | RP, C18 A: 0.12% aq. HFBA B: 0.12% aq. HFBA/30% MeOH | ESI-QqQ-MS/MS CAD MRM | internal | [ | |
| 6 | cataract | lense proteins | CML, MG-HI | increase of CML levels | HPLC-MS/MS | phosphate-buffered Saline/EDTA dialysis | acid, enzymatic 3 | OPA | RP, C18, A: 0.12% aq. HFBA B: 0.12% aq. HFBA/30% MeOH | ESI-QqQ-MS/MS, CAD MRM | external | [ |
| 7 | prion disease | Creutzfeldt- Jakob/brain scrapie/Syrian hamsters | CML, CEL | elevated AGE levels in plaques | GS-MS | CHCl3- CH3OH extraction | acid | esterify-cation (HCL, MeOH, CH2Cl2, C4F6O3) | HP-5MS column | EI-Q-MS | internal | [ |
| 8 | schizophrenia | plasma/schizophrenia | pentosidine | elevated level of AGEs | IP-RP- HPLC-Fluo | - | acid | - | RP, C18 A: 0.1% aq.HFBA B: 0.1% aq.HFBA/ACN | Fluo Ex/Em: 335/385 nm | external | [ |
| 9 | schizophrenia | plasma/schizophrenia | pentosidine | elevated level of AGEs | IP-RP- HPLC-Fluo | - | acid | - | RP, C18 A: 0.1% aq. HFBA B: 0.1% aq. HFBA/ACN | Fluo Ex/Em 335/385 nm | external | [ |
1 Pepsin, pronase E, aminopeptidase, prolidase; 2 collagenase, pronase E; 3 pronase E, leucine aminopeptidase, carboxypeptidase Y; %, %(v/v); ACN, acetonitrile; AGE, advanced glycation end products; AM, ammonium formate; CAD, collision-activated dissociation; CEA, N6-(carboxyethyl)arginine; CEL, N-(carboxyethyl)lysine; CMA, N6-(carboxymethyl)arginine; CML, N-(carboxymethyl)lysine; DM, Diabetes mellitus; DOLD, 3-deoxyglucosone-derived lysine dimer, 1,3-di(N-lysino)-4-(2,3,4-trihydroxybutyl)-imidazolium salt; EI, electron ionization; Ex/Em, excitation/emission wavelengths; ESI, electrospray ionization; FL, N-(fructosyl)lysine; Glarg, N-(5-hydro-4-imidazolon-2-yl)ornithine; GOLD, glyoxal-derived lysine dimer, 1,3-di(N-lysino)imidazolium salt; Fluo, fluorescent detection; GS-MS, gas chromatography–mass spectrometry; HFBA, heptafluorobutyric acid; HILIC, hydrophilic interaction liquid chromatography; HPLC, high-performance liquid chromatography; LC, liquid chromatography; MALDI-TOF, matrix assisted laser desorption/ionization time-of-flight; MeOH, methanol; MG-H1, (N-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine); MODIC, 2-ammonio-6-({2-[(4-ammonio-5-oxido-5-oxopentyl)amino]-4-methyl-4,5-dihydro-1H-imidazol-5-ylidene}amino)hexanoate; MOLD, methylglyoxal-derived lysine dimer; MRM, multiple reaction monitoring; MS, mass spectrometry; MS/MS, tandem mass spectrometry; NAL, N6-acetyllysine; NFL, N6-(formyl)lysine; NHDNS, Natural History of Diabetic Nephropathy Study; OPA, o-phthaldialdehyde; PFP, pentafluorophenyl; QMS, quadrupole mass analyzer; QqQ, triple quadrupole; RP, reversed phase; T1DM, Diabetes mellitus type 1; TFAME, trifluoroacetyl methyl ester; #, number.
Application of glycation adduct analysis in food research.
| # | Type of Food | Analyzed Adducts | Methodology | Ref. | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Technique | Protein Isolation | Protein Hydrolysis | Derivatization | Separation | Detection | Standardization | ||||
| 1 | milk products | CML | RP-HPLC -Fluo | Direct hydrolysis after reduction with 1 mol/L NaBH4 | acid | OPA | RP, C18 SpheriChROM RP-18 ODS, A: sodium acetate buffer (pH 6.50, 0.048 mol/L)/4% MeOH B: MeOH | Fluo Ex/Em: 340/455 nm | standard addition external | [ |
| 2 | milk products | CML, CEL, MG-H, FL, Argpyrimidine, 3DG-H, DOLD, Glarg, GOLD, MOLD | HPLC- MS/MS | Ultrafiltration (12 kDa cutoff) delipidation | enzymatic 1 | - | Hypercarb™ A: 26 mmol/L AM (pH 3.8) B: ACN | ESI-QqQ- MS/MS CAD MRM | internal | [ |
| 3 | milk products | CML | GS-MS | extraction: C2H6O-CH2Cl2 | acid | MeOH/TFAA | DB5-MS capillary column carrier helium | EI-IT-MS | internal, external, isotope dilution | [ |
| 4 | milk products | CML, furosine, CEL | HPLC–MS/MS | Hydrolyzed without protein isolation | acid | - | RP, C18 core shell Kinetex A: 5 mmol/L PFPA B: 5 mmol/L aq. PFBA/ACN | ESI-QqQ- MS/MS CAD MRM | internal | [ |
| 5 | milk products | CML | UHPLC–MS/MS | precipitation: TCA/extraction: CHCl3-MeOH | acid | - | RP, C18 Acquity UPLC™ BEC C18 column A: 0.13% aq. NFPA or 0.1% aq. TFA B: ACN | ESI-QqQ-MS/MS MRM | internal | [ |
| 6 | bakery products | CML, furosine, CEL | HPLC– MS/MS | - | acid | - | RP, C18 core shell Kinetex A: 5 mmol/L aq. PFPA B: 5 mmol/L aq. PFBA/ACN | ESI-QqQ- MS/MS CAD MRM | internal | [ |
| 7 | bakery products | CML | GS-MS | extraction: CHCl3-MeOH | acid | MeOH/TFAA | DB5-MS capillary carrier helium | EI-IT-MS | internal, external, isotope dilution | [ |
| 8 | bakery products | CML | HPLC–MS/MS | precipitation: TCA/extraction: CHCl3- MeOH | acid | - | RP, C18 Acquity BEH C18 column A: 0.13% aq NFPA or 0.1% aq. TFA B: ACN | ESI-QqQ- MS/MS CAD MRM | internal | [ |
| 9 | meat | CML | GS-MS | extraction: CHCl3-MeOH | acid | esterification by MeOH/acylation by TFAA | DB5-MS capillary carrier helium | EI-IT-MS | internal, external, isotope dilution | [ |
| 10 | meat | CML | HPLC–MS/MS | precipitation: TCA/extraction: CHCl3-MeOH | acid | - | RP, C18 Acquity BEH C18 col. A: 0.13% aq. NFPA or aq. 0.1% TFA B: ACN | ESI-QqQ- MS/MS CAD MRM | internal | [ |
| 11 | fish | CML | GS-MS | extraction: CHCl3-MeOH | acid | esterification by MeOH/acylation by TFAA | DB5-MS capillary carrier helium | EI-IT-MS | internal, external, isotope dilution | [ |
| 12 | coffee | melanoidins | Off line LC-MALDI-TOF-MS | Hot water extraction delipidation | - | - | GFC Sephadex G-25 | MALDI- TOF-MS | external | [ |
1 Pronase E, aminopeptidase, prolidase; %, % (v/v); ACN, acetonitrile; 3DG-H, N-(5-hydro-5-(2,3,4-trihydroxybutyl)-4-imidazolon-2-yl) ornithine and related structural isomers; CEL, N-(carboxyethyl)lysine; CML, N-(carboxymethyl)lysine; DOLD, 3-deoxyglucosone-derived lysine dimer, 1,3-di(N-lysino)-4-(2,3,4-trihydroxybutyl)-imidazolium salt; EI, electron ionization; ESI, electrospray ionization; FL, fructosyl-lysine; Fluo, fluorescent detection; IT, ion trap; GFC, gel-filtration chromatography; Glarg, N-(5-hydro-4-imidazolon-2-yl)ornithine; GOLD, glyoxal-derived lysine dimer, 1,3-di(N-lysino)imidazolium salt; GS-MS, gas chromatography–mass spectrometry; HPLC, high-performance liquid chromatography; LC, liquid chromatography; MALDI-TOF, matrix assisted laser desorption/ionization time-of-flight; MeOH, methanol; MG-H1, (N-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine); MOLD, methylglyoxal-derived lysine dimer; MRM, multiple reaction monitoring; MS, mass spectrometry; MS/MS, tandem mass spectrometry; NFPA, nonafluoropentanoic acid; OPA, o-phthaldialdehyde; PFPA, perfluoropentanoic acid; RP, reversed phase; QqQ, triple quadrupole; TCA, trichloroacetic acid; TFA, trifluoroacetic acid; TFAA, trifluoroacetic acid anhydride; UHPLC, ultra-high-performance liquid chromatography.